Environmental Monitoring Considerations

Slides:



Advertisements
Similar presentations
Microbiological Validation
Advertisements

Biopharmaceutical Quality
WHO - PSM Water –part 3 Workshop on GMP and Quality Assurance of HIV products Shanghai, China 28 Feb - 4 March 2005 Maija Hietava M.Sci.Pharm Quality Assurance.
Portavin integrated wine services A Bottling Perspective on Taints and Contributors to Variation.
Micro Risk Why do we clean so often? Does the cleaning make the product safer? Process Improvement & Product Services September
User requirements of a comprehensive ENVIRONMENTAL MONITORING software system Susan B. Cleary.
WHO - PSM Air Handling Systems Heating Ventilation and Air Conditioning (HVAC) – Part 1 Pharmaceutical Quality, Good manufacturing Practice & Bioequivalence.
World Health Organization
1 Utility Systems Process Systems – ‘Direct Impact Systems’ Contact the Product Contact Materials that will Ultimately Become Part of the Product Could.
Heating Ventilation and Air Conditioning (HVAC) – Part 3
Sterile Drug Process Inspections
Facility Design and CGMP Considerations for Cell Therapy Products
GTP Scenario # 2 September 17,2005. Scenario # 2 Dr. Good received IND approval for CD8 depletion of allogeneic PBMC for a Phase I/II clinical trial.
Basic Principles of GMP
SELECTING AND MANAGING CONTRACT STERILIZERS AND TESTING LABORATORIES
MONITORING CONTROLLED ENVIRONMENTS Pacific BioLabs Inc. (510)
Quality control of raw materials In-process control
MCC PRESENTATION - GMP MANUFACTURING ENVIRONMENTS
QC/QA Mary Malarkey Director, Division of Case Management Office of Compliance and Biologics Quality Center for Biologics Evaluation and Research March.
ISO Standard is based on the management model of plan – do - check – act. Today we all be discussing the elements of the standard that deal with.
Rob Packard, President Slide 1 of 23 Bioburden Failure Analysis An E. coli strain being plated for identification.
Rob Packard, President Slide 1 of 30 Bioburden Failure Analysis An E. coli strain being plated for identification.
Water | Slide 1 of 16 January 2006 Water for Pharmaceutical Use Part 4: Commissioning, Qualification and validation Supplementary Training Modules on Good.
World Health Organization
Qualification of HVAC systems
Radiopharmaceutical Production
World Health Organization
World Health Organization
Part 3: Design, qualification
A Basic Overview of the US FDA’s Regulations for Regulatory Compliance
Water | Slide 1 of Water for Pharmaceutical Use Part 3: Operational considerations Supplementary Training Modules on Good Manufacturing Practice.
Presented by Steven P. Feltman Food Safety and Quality Specialist.
IPQC: Definition:- Checks performed during production in order to monitor and, if necessary, to adjust the process to ensure that the product conforms.
World Health Organization
© Pharmaceutical Consultancy Services, All rights reserved. ENVIRONMENTAL MONITORING (VIABLES) Jaap Koster 1.
Part I: Introduction and overview
© Pharmaceutical Consultancy Services, All rights reserved. MEDIA FILLS Jaap Koster.
© Pharmaceutical Consultancy Services, All rights reserved. MEDIA FILLS Jaap Koster.
Important informations
Basics of Contamination Control
Moderated By Eyal Rivlin Lev Hakongressim, Weizmann Science Park, Ness Ziona May 2008.
Expectations for Facilities & cGMPs Biological Response Modifiers Advisory Committee Meeting October 9, 2003 Nicholas Obiri, Ph.D. CBER.
Validation | Slide 1 of 27 August 2006 Validation Supplementary Training Modules on Good Manufacturing Practice WHO Technical Report Series, No. 937, 2006.
PHARMACY IV ADMIXTURE Pharmacy 483 January 18, 2005 Kim Donnelly Affiliate Associate Professor.
Problem Management Scenario # 2 September 17,2005.
Clearance Testing and Procedures. Remediation Goals Eliminate contamination Eliminate source Thorough cleanup.
Sterile product validation
Module 3Slide 1 of 26 WHO - EDM Sanitation and Hygiene Basic Principles of GMP.
Pharmaceutical Quality Control & current Good Manufacturing Practice PHT 436 Lecture 4.
Environmental Control and Developing a Science-based Monitoring Program Richard L. Friedman, M.S. FDA/CDER.
Wyeth-Ayerst Pharmaceuticals1 CLEANING VALIDATION Microbial Monitoring Anthony M. Cundell Ph. D. Associate Director, QA Microbiological Development & Statistics.
Sterile Products Lab PHT 434
BSB Biomanufacturing CHAPTER 11 GMP – Pharmaceutical Water
USP 800 Implementation in a Community Oncology Practice
Pharmaceutical Quality Control & current Good Manufacturing Practice
Environmental Control & Support Processes
Author: Nurul Azyyati Sabri
World Health Organization
Quality Control and Assurance
FDA Guide To Aseptic Processing
Author: Nurul Azyyati Sabri
Water for Pharmaceutical Use
Laboratory facilities
Quality Systems in a Production Facility
Gene Therapy Production Facility Considerations
Sterile Products Lab PHT 434
Pharmaceutical Quality System in regard to Good Engineering Practice
Manufacture of Sterile Medicinal Products: Practical Examples
Manufacture of Sterile Medicinal Products: ‘Annex 1’ - DRAFT
Presentation transcript:

Environmental Monitoring Considerations Nancy Roscioli, Ph.D. Don Hill and Associates, Inc.

Environmental Monitoring Components Airborne nonviable particulate monitoring Airborne viable contaminant monitoring Viable contaminant monitoring of surfaces Viable contaminant monitoring of personnel Temperature and humidity monitoring Pressure differential monitoring

Environmental Monitoring Components Water monitoring: Total organic carbon Conductivity Microbial Contaminants Endotoxin

General Environmental Monitoring Considerations Monitoring frequencies and strategies Establishment of a meaningful and manageable program Sampling and testing procedures Establishment of effective alert and action limits Trending of results

General Environmental Monitoring Considerations Investigation and evaluation of trends as well as excursions from alert and action limits Corrective actions to be implemented in response to environmental monitoring excursions Personnel training - sampling, testing, investigating excursions, aseptic technique

Scope of Environmental Monitoring Program Should include monitoring of all environments where products and their components are manufactured All areas where there is a risk of product contamination Should include monitoring of all water used for product manufacturing as well as feed water to the final water purification system (WFI System)

Regulatory Basis for Environmental Monitoring Program CFR GMP regulations FDA Guidance Documents USP Informational Chapter

21 CFR 211.42 Aseptic processing areas: Easy to clean and maintain Temperature and humidity controlled HEPA filtered air Environmental monitoring system Cleaning and disinfecting procedures Scheduled equipment maintenance and calibration

21 CFR 211.46 Ventilation, air filtration, air heating and cooling: Adequate control over microorganisms, dust, humidity and temperature. Air filtration systems including prefilters and particulate matter air filters for air supplies to production areas.

Guideline on Sterile Drug Products Produced by Aseptic Processing Defines critical and controlled manufacturing areas Recommends airborne nonviable and viable contaminant limits Provides some guidance on monitoring frequencies for critical areas

Guideline on Sterile Drug Products Produced by Aseptic Processing Recommendations for air pressure differentials Includes guidance on aseptic media fills Note: This guidance document was written in 1987 and is in need of revision

Microbial Evaluation and Classification of Clean Rooms and Clean Zones USP General Information Chapter <1116> Establishment of clean room classifications Federal Standard 209E Importance of EM program Personnel training in aseptic processing Establishment of sampling plans and sites suggested sampling frequencies

Microbial Evaluation and Classification of Clean Rooms and Clean Zones Establishment of alert and action limits Suggests limits for airborne, surface and personnel contaminant levels. Methods and equipment for sampling Identification of isolates Aseptic media fills Emerging technologies - barrier; isolator

Federal Standard 209E “Airborne Particulate Cleanliness Classes in Clean Rooms and Clean Zones Approved by the GSA for use by all Federal Agencies Frequently referenced for controlled environment particulate requirements: Classes 100, 10,000 and 100,000 (based on particles > 0.5µ)

Guidance for Industry for Sterile Validation Process Validation in Applications for Human and Veterinary Drug Products Scope limited to final drug product manufacturing and data required for application submission (NDA, BLA) Requests information on: Buildings and facilities Manufacturing operations for drug product Filter validation Validation of hold times

Guidance for Industry for Sterile Validation Process Validation in Applications for Human and Veterinary Drug Products Requests information on: Sterilization and depyrogenation Media fills and actions taken when they fail Microbiological monitoring of the environment Airborne microorganisms, personnel, surfaces, water system, product component bioburden Yeasts, molds, anaerobes Exceeded EM limits

Viable and Nonviable Contaminant Limits

Controlled Area Preparation or manufacturing area where nonsterile product, in-process materials and product-contact equipment surfaces, containers and closures are exposed to the environment Control nonviable and viable contaminants to reduce product /process bioburden Class 100,000 or Class 10,000

Controlled Area Capping areas are now considered controlled manufacturing areas Should be supplied with HEPA filtered air Should meet class 100,000 conditions during static conditions

Critical Area Aseptic processing area where sterile products, components or in-process products are exposed to the environment and no further processing will occur. Air quality must be Class 100 during processing Local Class 100 areas are often utilized during open processing steps during drug substance manufacture.

Critical Area The area just preceding the sterile core should be one classification higher than the core.

Nonviable Particulate Monitoring Airborne cleanliness classifications should be met during operations Nonviable monitoring should occur routinely during operations Monitoring during static conditions is done as part of HVAC qualification and may be done periodically after that to insure area meets acceptable conditions before use or following cleaning

Nonviable Particulate Monitoring Locations for monitoring should be established during performance qualification; probes placed close to work surface Monitoring frequencies vary: For aseptic processing areas, during each use For other, controlled areas, varies from each use to weekly or less depending on use of area

Nonviable Particulate Monitoring HVAC Validation and Maintenance Considerations: Air velocity, airflow patterns and turbulence should be validated; smoke studies to determine flow patterns during static and dynamic conditions HEPA filter integrity testing HEPA filter efficiency testing Air pressure differentials

Microbial Monitoring Airborne viable contaminants Surface contaminants walls equipment surfaces countertops floors Personnel contaminants

Microbial Monitoring Monitoring methods should be capable of detecting molds and yeasts Should also be able to detect anaerobes Most often, this is an issue associated with products filled anaerobically (with nitrogen overlay) All lots of media for EM sampling should be growth promotion tested

Microbial Monitoring Routine microbial monitoring should take place during operations (for airborne contaminants) and immediately following operations (for surfaces and personnel). Airborne monitoring frequencies: Each use for aseptic processing areas Varies from daily to weekly to less frequently for controlled areas depending on use

Microbial Monitoring Personnel and surface monitoring frequencies vary: Aseptic processing - after every fill Other controlled areas - varies from daily to weekly or less for surfaces Personnel monitoring often restricted to aseptic area personnel and personnel working in Class 100 hoods performing tasks such as inoculation

Microbial Monitoring Monitoring of surfaces and airborne contaminants during rest periods (following cleaning) Important for confirming adequacy of cleaning procedures Indicates whether HVAC system is operating properly NOTE: Disinfectant effectiveness studies also required for cleaning agents used in the facility

Microbial Monitoring Monitoring frequencies and procedures are influenced by a number of factors: Stage of manufacturing “Open” or “closed” manufacturing step Single or multiple product manufacturing

Microbial Monitoring Establishment of monitoring locations should be based on performance qualification studies during dynamic conditions gridding study to determine worst case locations/most meaningful locations Should also establish common flora - will aid in investigations

Setting Alert and Action Limits Action limits (for the most part) have been established in a variety of guidance documents Alert limits Lower than action limits Reflect actual historical results under normal processing conditions

Exceeding Limits Alert limits are designed to provide some warning that environmental quality is approaching action limit and allow you time to correct. Exceeding alert limit triggers a warning response - i.e., alert affected area personnel Exceeding multiple alerts - triggers action level response

Exceeding Limits Action limit excursions require investigations Speciation of organism(s) Review batch records from date of excursion Review other recent EM data (trends) Review cleaning records Interview personnel Product impact - must quarantine until determined

Exceeding Limits Excursions from action limits require corrective actions that may include: More rigorous or additional monitoring More rigorous cleaning Retraining of personnel Procedural changes - change to or addition of disinfection procedures, for example HVAC maintenance

Investigations and Corrective Actions The investigation procedures to be followed should be pre-established and included in SOPs Depending on the outcome of the investigation, corrective actions should be pre-established to the extent possible

Investigations and Corrective Actions Imperative that EM results be linked to product release so that affected products are not released until investigation completed Material Review Board or equivalent should be consulted prior to releasing product that was potentially affected by adverse environmental conditions

Trending Should trend monitoring results (environmental and water) Periodic (quarterly or monthly) review by QA and others Re-evaluation of action and alert limits on an annual basis This trending information is generally included in the Annual Product Review

Temperature and Humidity Control of temperature and humidity required for aseptic processing areas 21 CFR 211.42(c)(10)(ii) Generally 65°F and 35-50% humidity are average Too high - Increases personnel shedding Too low - Increase static electricity

Temperature and Humidity Temperature should be controlled throughout all manufacturing areas Temperature and humidity should be monitored and controlled in warehouse areas where temperature/humidity sensitive raw materials are stored If not able to control humidity, need procedure to follow if humidity exceeds limit

Water Requirements

Water For Injection Defined by USP Water purified by distillation or reverse osmosis Prepared from water complying with the U.S. EPA National Primary Drinking Water Regulations Contains no added substance

Purified Water Defined in USP Obtained by a suitable process, usually one of the following: deionization reverse osmosis combination

Potable Water Meets National Drinking Water Regulations 40 CFR Part 141 Periodic monitoring in-house as well as periodic certificates from municipality (if applicable)

Water System Monitoring WFI Systems Microbial quality and endotoxin Daily system monitoring Each use point at least weekly TOC and Conductivity Weekly system monitoring can be taken from worst case point (end of loop, return to tank)

Water System Monitoring Purified Water Systems Weekly monitoring of system for: microbial quality TOC conductivity

Water Use WFI Solvent for preparation of parenteral solutions Formulation of mammalian cell culture media Formulation of purification buffers Final product formulation Vial and stopper washing Final rinse for product equipment

Water Use Purified Water Preparation of terminally sterilized microbiological media Initial rinsing/cleaning Laboratory use Feed for WFI system

Water Use Potable Water Non-product contact uses Feed for purified water system

Microbial Monitoring Devices Slit-to-Agar (STA) - Powered by vacuum, air taken in through a slit below which is a slowly revolving plate. Sieve impactor - Vacuum draws in air through perforated cover which is impacted onto petri dish containing nutrient agar

Microbial Monitoring Devices Centrifugal Sampler - consists of a propeller that pulls a known volume of air into the unit and then propels the air outward to impact on a nutrient agar strip Sterilizable Microbiological Atrium (SMA)- similar to sieve impactor; cover contains uniformly spaced orifices; vacuum draws in air which is impacted on agar plate

Microbial Monitoring Devices Surface Air System Sampler - An integrated unit containing an entry section with an agar contact plate; behind is a motor and turbine that pulls air in through the perforated cover and exhausts it beyond the motor. Settle plates - qualitative; may be useful in worst case locations

Microbial Monitoring Devices Surface contaminant monitoring devices: Contact Plates - plates filled with nutrient agar; for regular surfaces Swabs - useful for hard to reach or irregular surfaces; swab placed in suitable diluent and inoculated onto microbiological plate

Monitoring Considerations Remote sampling probes - validate use of tubing Must sample adequate quantity of air to be statistically meaningful. 80-100 ft3/min Must validate growth promotion after exposure of settle plates (or other plates) for prolonged time periods.